|
Effects of sacubitril valsartan sodium tablets on cardiac function and neurotransmitters in elderly patients with chronic heart failure complicated with anxiety and depression
HUANG Chunhui, ZHANG Wei, ZHENG Yonghong, LIN Song
2025, 39 (8):
793-797.
doi: 10.3969/j.issn.1003-9198.2025.08.008
Objective To investigate the effects of sacubitril valsartan sodium tablets (ARNI) on cardiac function and neurotransmitter indicators in the elderly patients with chronic heart failure (CHF) complicated with anxiety and depression. Methods A total of 120 elderly patients with CHF complicated with anxiety and depression admitted to our hospital from January 2021 to December 2023 were enrolled. They were randomly divided into observation group (60 cases) and control group (60 cases). The control group received conventional treatment for heart failure (furosemide, angiotensin-converting enzyme inhibitor, metoprolol succinate sustained-release tablets, and spironolactone), while the observation group received ARNI, furosemide, metoprolol succinate sustained-release tablets, and spironolactone. The treatment duration was 3 months in both groups. The score of anxiety and depression scale, New York Heart Association (NYHA) cardiac function classification, 6-minute walk distance (6MWD), the score of Minnesota Living with Heart Failure Questionnaire (MLHFQ), the levels of the echocardiographic indicators such as left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), the levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), and serotonin (5-HT), dopamine (DA), and norepinephrine (NE) were compared between the two groups. Results After treatment, the observation group showed significantly better outcomes in the score of anxiety and depression scale, NYHA cardiac function classification, 6MWD, the score of MLHFQ, the levels of echocardiographic parameters (LVEDD, LVESD, LVEF), NT-proBNP, and neurotransmitters (5-HT, DA, NE) compared to the control group (P<0.05). Conclusions ARNI, when routinely used in the treatment of elderly patients with CHF complicated with anxiety and depression, can improve clinical efficacy, cardiac function and life quality, and alleviate anxiety and depression. The potential mechanisms may be related to increased neurotransmitter levels, reduced myocardial oxidative stress damage, improved antioxidant capacity, and delayed myocardial remodeling.
References |
Related Articles |
Metrics
|